Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes (Q34642403)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q96200428)
(Q91522188)
(Q6490646)
(Q80374692)
(Q88022461)
(Q114427998)
(Q91632799)
(Q114726224)
(Q114726255)
(P304) 4161-4167
(P407) (Q1860)
(P433) 33
(P478) 30
(P577) Monday, September 10, 2012
(P921) (Q181600)
(P1433) (Q400292)
(P1476) "Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes" (language: en)
(P2093) Jatin Shah
Stefan Hart
Jeanette Wood
Ramesh Jayaraman
Kantharaj Ethirajulu
Joy Zhu
(P2860) (Q42720284)
(Q37989935)
(Q33399980)
(Q35925127)
(Q37948366)
(Q34194226)
(Q35112864)
(Q34186734)
(Q34627911)
(Q33632062)
(Q35034487)
(Q37003892)
(Q36508931)
(Q36407235)
(Q36740971)
(Q36701486)
(Q33236181)
(Q36373661)
(Q40399429)
(Q40484560)
(Q40486172)
(Q40862621)
(Q41454639)
(Q41604885)
(Q47582438)
(Q46506090)
(Q57479568)
(Q57571451)
(Q72554769)
(Q85087797)
(Q80673257)
(Q84210122)
other details
description scientific article

External Links